Candida in the ICU

Clinics in Chest Medicine

Volumn 30, Issue 2, 2009, Pages 287-293

  Darouiche, Rabih O ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Candida; Candidemia; Candidiasis; Deep seated infection; ICU; Invasive infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CANDIDA; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

CANDIDIASIS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS;

EID: 64349119998     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.02.013     Document Type: Review

References (41)

1. Eggimann P., Garbino J., and Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3 11 (2003) 685-702
2. DiNubille M.J., Lupinacci R.J., Strohmaier K.M., et al. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 22 3 (2007) 237-244
3. Magnason S., Kristinsson K.G., Stefansson T., et al. Risk factors and outcome in ICU-acquired infections. Acta Anaesthesiol Scand 52 9 (2008) 1238-1245
4. Ben-Ami R., Weinberger M., Orni-Wasserlauff R., et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 46 7 (2008) 2222-2226
5. Klotz S.A., Chasin B.S., Powell B., et al. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 59 4 (2007) 401-406
6. Suljagić V., Cobeljić M., Mirović V., et al. Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control 33 6 (2005) 333-340
7. Bouza E., and Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 32 Suppl 2 (2008) S87-S91
8. Chow J.K., Golan Y., Ruthazer R., et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 46 8 (2008) 1206-1213
9. Krmercy V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50 4 (2002) 243-260
10. Playford E.G., Marriott D., Nguyen Q., et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36 7 (2008) 2034-2039
11. Dimopoulos G., Ntziora F., Rachiotis G., et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 106 2 (2008) 523-529
12. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 9 (2005) 1232-1239
13. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30 4 (2000) 662-678
14. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 2 (2004) 161-189
15. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331 20 (1994) 1325-1330
16. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 10 (2003) 1221-1228
17. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 9495 (2005) 1435-1442
18. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 25 (2002) 2020-2029
19. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 24 (2007) 2472-2482
20. Kuse E.R., Chetchotisakd P., de Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 9572 (2007) 1519-1527
21. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 7 (2007) 883-893
22. Anaissie E.J., Darouiche R.O., Abi-Said D., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23 5 (1996) 964-972
23. Rex J.H., Bennett J.E., Sugar A.M., et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycosis Study Group and the Candidemia Study Group. Clin Infect Dis 21 4 (1995) 994-996
24. Raad I., Hanna H., Boktour M., et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38 8 (2004) 1119-1127
25. Pasqualotto A.C., de Moraes A.B., Zanini R.R., et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 28 7 (2007) 799-804
26. De Pauw B.E., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 45 12 (2008) 1813-1821
27. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 1 (2006) 25-31
28. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk for hospital mortality. Antimicrobial Agents Chemother 49 9 (2005) 3640-3645
29. Schuster M.G., Edwards Jr. J.E., Sobel J.D., et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149 2 (2008) 83-90
30. Golan Y., Wolf M.P., Pauker S.G., et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 143 12 (2005) 857-869
31. Chen H., Suda K.J., Turpin R.S., et al. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: cost-effectiveness analysis. Curr Med Res Opin 23 5 (2007) 1057-1065
32. Shorr A.F., Lazarus D.R., Sherner J.H., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35 4 (2007) 1077-1083
33. Klevay M.J., Ernst E.J., Hollanbaugh J.L., et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 60 3 (2008) 273-277
34. Tumbarello M., Sanguinetti M., Trecarichi E.M., et al. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 62 6 (2008) 1379-1385
35. Cheung C., Guo Y., Gialanella P., et al. Development of candidemia on caspofungin therapy: a case report. Infection 34 6 (2006) 345-348
36. Kojic E.M., and Darouiche R.O. Comparison of adherence of Candida albicans and Candida parapsilosis to silicone catheters in vitro and in vivo. Clin Microbiol Infect 9 7 (2003) 684-690
37. Kojic E.M., and Darouiche R.O. Candida infections of medical devices. Clin Microbiol Rev 17 2 (2004) 255-267
38. Lewis R.E., Kontoyiannis D.P., Darouiche R.O., et al. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrobial Agents Chemother 46 11 (2002) 3499-3505
39. Mukherjee P.K., Long L., Kim H.G., et al. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 33 2 (2009) 149-153
40. Schinabeck M.K., Long L.A., Hossain M.A., et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrobial Agents Chemother 48 5 (2004) 1727-1732
41. Darouiche R.O. Treatment of infections associated with surgical implants. N Engl J Med 350 14 (2004) 1422-1429